July 31, 2008 |
Allergan Inc., maker of the wrinkle smoother Botox, said second-quarter profit rose 6.9% as overseas sales of facial treatments and prescription eye-care products helped the Irvine company weather a slowing U.S. economy. Net income increased to $147.3 million, or 48 cents a share, from $137.8 million, or 45 cents, a year earlier. Adjusted profit of 63 cents a share matched analysts' estimates. Revenue climbed 20% to $1.17 billion, topping the average estimate of $1.14 billion in a Bloomberg survey.
July 10, 2008 |
More than a dozen Botox users and relatives filed a lawsuit Wednesday contending that the blockbuster wrinkle-buster injured them or killed their relatives, and they blamed maker Allergan Inc. for failing to warn them of the dangers. The suit, filed in Orange County Superior Court near Allergan's Irvine headquarters, links the toxin-based drug to three deaths, including one in March of a 69-year-old Texas nurse who received injections for neck and shoulder pain.
June 5, 2008 |
Allergan Inc., maker of the wrinkle remover Botox, said it would ask U.S. regulators by the end of the third quarter to approve a drug for use in stimulating eyelash growth. The medicine, bimatoprost, is applied directly to the base of the eyelashes and has resulted in "significant eyelash growth" in clinical testing, the Irvine-based company said.
May 8, 2008 |
Allergan Inc.'s net income more than doubled in the first quarter as sales accelerated outside the U.S. for the wrinkle remover Botox. Demand cooled in the U.S., and the company blamed the economy. Net income increased to $111.4 million, or 36 cents a share, from $43.8 million, or 14 cents, a year earlier, the company said. Revenue grew 23% to $1.08 billion, bolstered by converting overseas sales in other currencies to the dollar. Irvine-based Allergan sells cosmetic and medical products including breast implants, surgical devices to remedy obesity and a treatment for overactive bladders.
March 5, 2008 |
The U.S. Department of Justice is looking at Allergan Inc.'s promotion of its blockbuster wrinkle drug Botox for medical uses, but investors didn't seem too worried about the news Tuesday. Allergan shares closed at $57.38, down $1.28 or 2.2% on word that the Irvine company received a subpoena from the U.S. Attorney's Office for the Northern District of Georgia demanding documents regarding its promotional and educational practices involving the use of the botulinum toxin-based drug for medical problems.
November 26, 2007 |
In his corner office, Mr. Botox looked his age. He hadn't had a shot of botulinum toxin in a while, and the furrow between his brows was back. "You would never know I'm really 75 years old," David E.I. Pyott said, trotting out a well-worn joke that he likes to make "because of who I am." He's the man who made a muscle-controlling poison the most fashionable weapon against aging. And he's really 54. When Allergan Inc. hired him as chief executive in 1998, it was generating annual revenue of $1.
November 20, 2007 |
Allergan Inc., the maker of the glaucoma treatment Lumigan, sued seven companies it said were improperly selling related products as ways to grow eyelashes. The companies sell cosmetics with names such as MassiveLash, DermaLash, Luxette, Age Intervention and MD Lash Factor, Allergan said Nov. 7 in a lawsuit filed in U.S. District Court in Santa Ana. All contain compounds called prostaglandins and infringe a patent for using the substance to grow eyelashes, the company said.
November 7, 2007
Allergan Inc., the Irvine-based maker of the wrinkle smoother Botox, said Tuesday that third-quarter profit rose 48% on sales of the product, breast implants and eye drops. Net income jumped to $157.4 million, or 51 cents a share, from $106.4 million, or 35 cents, a year earlier, the company said. Excluding certain items, profit matched the 58-cent average estimate of analysts surveyed by Bloomberg. Revenue increased 23% to $993.7 million.
September 20, 2007 |
Irvine-based Allergan Inc. -- which is testing its beauty drug Botox as a tonic for overactive bladders -- plans to buy Esprit Pharma Inc. and its U.S. rights to a urinary incontinence drug. Allergan said Wednesday that it had agreed to pay $370 million in cash for Esprit, which sells the incontinence drug Sanctura under a U.S. license from Indevus Pharmaceuticals Inc. Esprit would be Allergan's first major purchase since 2005, when it acquired Inamed Corp.